Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 20/20 | 0.59 |
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.59 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HRH2 | P25021 | 1/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5117023 | 0.84 | TLR7 (0.61) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL2058836 | 0.83 | TLR7 (0.65) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL5451786 | 0.83 | LMNA (0.39) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL6274058 | 0.82 | TLR7 (0.59) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL1490612 | 0.81 | TLR7 (0.71) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL5808532 | 0.80 | TLR7 (0.64) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL2058824 | 0.80 | TLR7 (0.54) | TLR7TLR8NUDT1LMNAPOLB | |
| Trifluoroacetic Acid SCHEMBL2059401 | 0.80 | TLR7 (0.54) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL3872728 | 0.79 | TLR7 (0.71) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL5122832 | 0.79 | TLR7 (0.69) | TLR7TLR8NUDT1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259881-A1 | Substituted Imidazo Ring Systems and Methods | COLEY PHARMACEUTICAL GROUP, INC. | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259881-A1 | Substituted Imidazo Ring Systems and Methods | IL2, IL4, IRF3 | TLR7 55/4885TLR8 93/4885NUDT1 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.